Loading company…
Ruoyi Bio develops macromolecular drug delivery technologies and related products.
Ruoyi Bio develops drug delivery technologies, including a zinc finger protein platform and an insect cell-baculovirus production process. Its pipeline includes recombinant botulinum toxin protein drugs and intracellular antibodies for tumors and infectious diseases. Founded in 2018, the Shanghai company raised Series A funding in March 2026 from Kunshan Guoke Venture Investment and Qiji Gongjin (Shanghai) Life Science Partnership (Limited Partnership).
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in